Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid

被引：0

作者：

Coelho, T. ^{[1
]}

Maia, L. ^{[1
]}

Martins da Silva, A. ^{[1
]}

Waddingtion-Cruz, M. ^{[2
]}

Plante-Bordeneuve, V. ^{[3
]}

Lozeron, P. ^{[4
]}

Suhr, O. B. ^{[5
]}

Campistol, J. ^{[6
]}

Conceicao, I. M. ^{[7
]}

Schmidt, H. ^{[8
]}

Trigo, P. ^{[9
]}

Packman, J. ^{[10
]}

Grogan, D. R. ^{[10
]}

机构：

[1] Hosp Santo Antonio, Dept Neurophysiol, Oporto, Portugal

[2] Univ Fed Rio de Janeiro, Univ Hosp, Neurol Serv, BR-21941 Rio De Janeiro, Brazil

[3] CHU Henri Mondor, Dept Neurol, F-94010 Creteil, France

[4] CHU Bicetre, Dept Neurol, Le Kremlin Bicetre, France

[5] Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden

[6] Hosp Clin Barcelona, Renal Transplant Unit, Barcelona, Spain

[7] Hosp Santa Maria, Dept Neurol, Lisbon, Portugal

[8] Univ Klinikum Munster, Munster, Germany

[9] FLENI, Buenos Aires, DF, Argentina

[10] FoldRx Pharmaceut Inc, Cambridge, MA USA

来源：

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2010年 / 17卷

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：75 / 76

页数：2

共 50 条

[41] Development of a first-in-class autologous B cell therapy for the treatment of Fabry disease
Elliott, Eileen
Romano, Rosa
Arenas, Johnny
Ahene, Ago
Casanova, Inosencio
Chang, Robert
Bengford, David
Hernandez, Moises
Li, Grant
Pios, Ariel
Rajendiran, Smrithi
Somebang, Kerri
Zepecki-France, Kolton
Brennan, Thomas
Boyle, Kathleen
Rakestraw, James A.
MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
[42] Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials
Grill, Joshua D.
Karlawish, Jason
NEUROLOGY, 2021, 97 (10) : 496 - 500
[43] ACCESS TO A FIRST DISEASE-MODIFYING THERAPY LEADS TO A DISPROPORTIONATE INCREASE IN THE PATIENT POPULATION DIAGNOSED WITH A RARE DISEASE
Tschumi, B.
Louet, E.
Steinbach, K.
Phillips, G.
Robbins, S.
VALUE IN HEALTH, 2023, 26 (12) : S218 - S218
[44] Disease-modifying effect of circuit class therapy in patients with relapsing-remitting multiple sclerosis
Kolcava, J.
Vlckova, E.
Kocica, J.
Sladeckova, M.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 395 - 396
[45] Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)
Vachani, Pankit
Lange, Andrzej
Delgado, Regina Garcia
Al-Ali, Haifa Kathrin
Hernández-Rivas, Jesus Maria
Kiladjian, Jean-Jacques
Vannucchi, Alessandro
Perkins, Andrew Charles
Valmeekam, Venu
Krejsa, Cecile Marie
Uyei, Anne
McGreivy, Jesse
Rothbaum, Wayne P.
Mascarenhas, John
Verstovsek, Srdan
BLOOD, 2021, 138
[46] First Evidence for Disease-Modifying Treatment of SLC20A2-Related Primary Familial Brain Calcification
Balck, Alexander
Klein, Christine
MOVEMENT DISORDERS, 2024, 39 (12) : 2180 - 2180
[47] Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis
Tedeholm, H.
Piehl, F.
Lycke, J.
Link, J.
Stawiarz, L.
Burman, J.
de Flon, P.
Fink, K.
Gunnarsson, M.
Mellergard, J.
Nilsson, P.
Sundstrom, P.
Svenningsson, A.
Johansson, H.
Andersen, O.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
[48] Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis
Tedeholm, H.
Piehl, F.
Lycke, J.
Link, J.
Stawiarz, L.
Burman, J.
de Flon, P.
Fink, K.
Gunnarsson, M.
Mellergard, J.
Nilsson, P.
Sundstrom, P.
Svenningsson, A.
Johansson, H.
Andersen, O.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
[49] TAFAMIDIS DELAYS DISEASE PROGRESSION COMPARABLY ACROSS VAL30MET AND NON-VAL30MET GENOTYPES IN TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY
Gundapaneni, B.
Sultan, M. B.
Keohane, D. J.
Schwartz, J.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 (03) : 294 - 294
[50] FACTORS INFLUENCING SELECTION OF FIRST ADD-ON DISEASE-MODIFYING THERAPY FOR RHEUMATOID ARTHRITIS AFTER STARTING METHOTREXATE
Huang, Y.
Agarwal, S.
Chen, H.
Johnson, M. L.
Chatterjee, S.
Aparasu, R. R.
VALUE IN HEALTH, 2022, 25 (07) : S503 - S503

← 1 2 3 4 5 →